Top Stories
Australia’s CSL reaffirms commitment to making AstraZeneca COVID vaccine
Published by maria gbaf
Posted on October 14, 2021
1 min readLast updated: January 29, 2026
Global Banking & Finance Review®
Company
Published by maria gbaf
Posted on October 14, 2021
1 min readLast updated: January 29, 2026
CSL remains committed to producing AstraZeneca's COVID-19 vaccine in Australia, despite growing demand for Pfizer and Moderna alternatives.
(Reuters) – Australian biotech CSL said on Thursday it was committed to its agreement for the production of about 50 million doses of AstraZeneca’s COVID-19 vaccine into 2022.
The announcement came after a media report said the British drugmaker’s vaccine, Vaxzevria, will no longer be manufactured in Australia due to demand for vaccines of Pfizer and Moderna. [nL4N2R91XR]
Pfizer and Moderna have established a market dominance by using mRNA-based COVID-19 vaccine technology to fight the pandemic.
CSL, in a brief statement, added that more than 20 million of the doses have already been produced, and it is expected that the remaining production will be completed early next year.
Cafes, gyms and restaurants in Sydney welcomed back fully vaccinated customers earlier this week after nearly four months of a lockdown, as Australia aims to begin living with the coronavirus and gradually reopen with high rates of inoculation.
(Reporting by Indranil Sarkar in Bengaluru; Editing by Maju Samuel)
The article discusses CSL's commitment to producing AstraZeneca's COVID-19 vaccine in Australia amid changing market demands.
A media report suggested production might stop due to increased demand for Pfizer and Moderna vaccines.
CSL has produced over 20 million doses of AstraZeneca's vaccine.
Explore more articles in the Top Stories category
